NIBEC Reports Q1 2026 Net Profit Turnaround and Highlights NP-201 License-out Deal

Q1 2026 consolidated sales KRW 5.24B, operating profit KRW 0.14B, net profit KRW 1.15B, turning profitable YoY
NP-201 (pulmonary fibrosis) global license-out deal signed May 2025: $8M upfront received, total up to $435M + 4% royalties
Cash and equivalents KRW 22.6B, debt ratio 35.3%, stable financial structure
R&D expenses KRW 1.44B (27.5% of sales), peptide pipeline (obesity, sarcopenia, periodontitis) in Ph1/2 clinical trials
Tissue regeneration biomaterials sales KRW 5.16B (98.45% of total), global distribution via Straumann & Nobel Biocare
Accumulated deficit KRW 49.8B, high customer concentration (top 3 account for 80% of sales)
Outstanding 8th CB KRW 258M (conversion price KRW 21,175), potential dilution
No dividends or share buyback/cancellation planned